Cargando…
P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
Autores principales: | Reiter, A., Gotlib, J., Álvarez-Twose, I., Radia, D. H., Luebke, J., Bobbili, P. J., Wang, A., Norregaard, C., Dimitrijević, S., Sullivan, E., Louie-Gao, M., Schwaab, J., Galinsky, I. A., Perkins, C., Sperr, W. R., Sriskandarajah, P., Chin, A., Sendhil, S. R., Duh, M. S., Valent, P., DeAngelo, D. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429350/ http://dx.doi.org/10.1097/01.HS9.0000846924.89785.04 |
Ejemplares similares
-
P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022) -
P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022) -
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022) -
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022) -
Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)